Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by talisman47on Aug 18, 2020 3:58pm
220 Views
Post# 31424703

AGN , Facebook interview today

AGN , Facebook interview todayInterview was excellent.My takeaway was :

If they almost  have almost half the people enrolled in the Covid trial now  they should be 100% enrolled in next two weeks or so. Then two weeks after that for data and another couple of weeks from that to determine data and  publically come out with results. That could possibly be around the end of September ???

The second trial, chronic cough  , takes about five months { done in Australia for financial reasons } before for it's over and results are public.  Their existing data seems to show they are going to get good results from this trial and that chronic cough is a big problem world wide with lots of opportunity.

Also, could be some interest from large pharma type companies on one or both of these trials. The big pharmas may be waiting to see how phase 2 goes before maybe giving more serious interest in AGN.


It was a good summary of where thery are  at and certainly Moreau gives a positive vibe of good things to come if phase 2 goes well. Makes me think they have several irons in the fire going at this point and we now wait and see how it plays out.

Stay positive.....


<< Previous
Bullboard Posts
Next >>